Up to date information and news regarding the protozoan parasite
Friday, March 27, 2015
Attenuated Toxoplasma gondii stimulates immunity to pancreatic cancer by manipulation of myeloid cell populations
Cancer Immunol Res.
2015 Mar 24. pii: canimm.0235.2014. [Epub ahead of print]
Suppressive myeloid cells represent a significant barrier to the generation of productive anti-tumor immune responses to many solid tumors. Eliminating or reprogramming suppressive myeloid cells to abrogate tumor-associated immune suppression is a promising therapeutic approach. We asked whether treatment of established aggressive disseminated pancreatic cancer with the immunotherapeutic attenuated Toxoplasma gondii vaccine strain CPS would trigger tumor-associated myeloid cells to generate therapeutic anti-tumor immune responses. CPS treatment significantly decreased tumor-associated macrophages and markedly increased dendritic cell infiltration of the pancreatic tumor microenvironment. Tumor-resident macrophages and dendritic cells, particularly cells actively invaded by CPS, increased expression of co-stimulatory molecules CD80 and CD86 and concomitantly boosted their production of IL-12. CPS treatment increased CD4
T cell infiltration into the tumor microenvironment, activated tumor-resident T cells, and increased IFN-γ production by T cell populations. CPS treatment provided a significant therapeutic benefit in pancreatic tumor-bearing mice. This therapeutic benefit depended on IL-12 and IFN-γ production, MyD88 signaling, and CD8
T cell populations. Although CD4
T cells exhibited activated effector phenotypes and produced IFN-γ, CD4
T cells as well as NK cells were not required for the therapeutic benefit. In addition, CD8
T cells isolated from CPS treated tumor-bearing mice produced IFN-γ after re-exposure to pancreatic tumor antigen, suggesting this immunotherapeutic treatment stimulated tumor cell antigen-specific CD8
T cell responses. This work highlights the potency and immunotherapeutic efficacy of CPS treatment and demonstrates the significance of targeting tumor-associated myeloid cells as a mechanism to stimulate more effective immunity to pancreatic cancer.
Copyright © 2015, American Association for Cancer Research.
[PubMed - as supplied by publisher]
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)